@inproceedings{inproceedings, title  = {{A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Jones RJ and Hussain SA and Birtle AJ and Song YP and Enting D and Faust G and Hilman S and Jagdev S and McGovern UB and Parikh O and Lewis A et al}},

 volume = {{40}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{17}},

 note = {{Accessed on 2024/12/21}}}